undefined cover
undefined cover
Advocacy in rare disease: Surveying the landscape cover
Advocacy in rare disease: Surveying the landscape cover
Life and Science

Advocacy in rare disease: Surveying the landscape

Advocacy in rare disease: Surveying the landscape

57min |11/05/2023|

34

Play
undefined cover
undefined cover
Advocacy in rare disease: Surveying the landscape cover
Advocacy in rare disease: Surveying the landscape cover
Life and Science

Advocacy in rare disease: Surveying the landscape

Advocacy in rare disease: Surveying the landscape

57min |11/05/2023|

34

Play

Description

In this podcast, first episode in the 2023 Science/AAAS Fondation Ipsen series on advocacy in rare disease, our guests examine the advocacy landscape, asking: what does advocacy entail,
who are advocates, what organizations are involved with rare disease
advocacy, what determines how umbrella organizations allocate resources,
and what is effective—examining success stories of when advocacy has
worked.


With: 

Durhane Wong-Rieger, Ph.D. (Canadian Organization for Rare Disorders (CORD), Ontario, Canada)
Michael Manganiello (Pyxis Partners, Washington, DC)
Marc C. Patterson, M.D. (Mayo Clinic, Rochester, MN)
Flaminia Macchia, M.A. (Roche, Brussels, Belgium)

And Erika Gebel Berg, Ph.D., our moderator


Hosted by Ausha. See ausha.co/privacy-policy for more information.

Description

In this podcast, first episode in the 2023 Science/AAAS Fondation Ipsen series on advocacy in rare disease, our guests examine the advocacy landscape, asking: what does advocacy entail,
who are advocates, what organizations are involved with rare disease
advocacy, what determines how umbrella organizations allocate resources,
and what is effective—examining success stories of when advocacy has
worked.


With: 

Durhane Wong-Rieger, Ph.D. (Canadian Organization for Rare Disorders (CORD), Ontario, Canada)
Michael Manganiello (Pyxis Partners, Washington, DC)
Marc C. Patterson, M.D. (Mayo Clinic, Rochester, MN)
Flaminia Macchia, M.A. (Roche, Brussels, Belgium)

And Erika Gebel Berg, Ph.D., our moderator


Hosted by Ausha. See ausha.co/privacy-policy for more information.

Share

Embed

You may also like

Description

In this podcast, first episode in the 2023 Science/AAAS Fondation Ipsen series on advocacy in rare disease, our guests examine the advocacy landscape, asking: what does advocacy entail,
who are advocates, what organizations are involved with rare disease
advocacy, what determines how umbrella organizations allocate resources,
and what is effective—examining success stories of when advocacy has
worked.


With: 

Durhane Wong-Rieger, Ph.D. (Canadian Organization for Rare Disorders (CORD), Ontario, Canada)
Michael Manganiello (Pyxis Partners, Washington, DC)
Marc C. Patterson, M.D. (Mayo Clinic, Rochester, MN)
Flaminia Macchia, M.A. (Roche, Brussels, Belgium)

And Erika Gebel Berg, Ph.D., our moderator


Hosted by Ausha. See ausha.co/privacy-policy for more information.

Description

In this podcast, first episode in the 2023 Science/AAAS Fondation Ipsen series on advocacy in rare disease, our guests examine the advocacy landscape, asking: what does advocacy entail,
who are advocates, what organizations are involved with rare disease
advocacy, what determines how umbrella organizations allocate resources,
and what is effective—examining success stories of when advocacy has
worked.


With: 

Durhane Wong-Rieger, Ph.D. (Canadian Organization for Rare Disorders (CORD), Ontario, Canada)
Michael Manganiello (Pyxis Partners, Washington, DC)
Marc C. Patterson, M.D. (Mayo Clinic, Rochester, MN)
Flaminia Macchia, M.A. (Roche, Brussels, Belgium)

And Erika Gebel Berg, Ph.D., our moderator


Hosted by Ausha. See ausha.co/privacy-policy for more information.

Share

Embed

You may also like